Uncategorized

jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa

by Business Wire • 2020/07/27 • 0 Comments

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa

← 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia

Global Ophthalmology Devices Market Analysis Highlights the Impact of COVID-19 2020-2024 | Increasing Prevalence of Ophthalmic Diseases to Boost Market Growth | Technavio →